|
Trials
|
Patients
|
Regimen
|
pCR
|
|---|
| | |
Tumor
|
cLN+
| |
Breast + LN
|
Breast
|
|---|
| |
Stage
|
>4 cm
|
(%)
| |
+CIS*
|
–CIS**
|
+CIS
|
–CIS
|
|---|
|
This study
|
T1-4c, N1-3
|
45%
|
100%
|
AC→SD
|
22.5%
|
NA
|
30.6%
|
22.5%
|
|
NSAPB B-27 [3]
|
T1c-3, N0-1
|
45%
|
30%
|
AC
|
11.5%
|
NA
|
13.7%
|
9.6%
|
| | |
45%
|
30%
|
AC→D
|
21.8%
|
NA
|
26.1%
|
18.9%
|
|
GEPARDUO [13]
|
T2-3, N0-2
|
32%
|
38%
|
AD
|
NA
|
7.0%
|
11.0%
|
7.0%
|
| | |
33%
|
42%
|
AC→D
|
NA
|
14.3%
|
22.3%
|
15.9%
|
-
A, doxorubicin; C, cyclophosphamide; CIS, carcinoma in situ; cLN, clinically detected lymph node; D, docetaxel; NA, non-assessable; S, S-1. ‘* + CIS’ or ‘**–CIS’ indicates that the definition of pCR includes or does not include CIS.
